Richard Francis, Teva Pharmaceuticals CEO, joins CNBC's 'Money Movers' to discuss the company's most recent quarter, what's ...

In its third quarter, Teva booked revenue of $4.48 billion. That was 3% higher year over year, and much of that growth came ...

Teva Pharmaceutical Industries reported on Wednesday a higher-than-expected rise in third-quarter profit, helped by strong ...

Revenues grew by 3.4 percent to $4.48 billion from $4.33 billion year-on-year, on the back of strong growth across its brands ...

Teva Pharmaceuticals USA, based in Parsippany, New Jersey, issued a voluntary recall on Oct. 7 for some of the prazosin ...

Even with Inflation Reduction Act (IRA)-related pressure looming for its top product, Teva Pharmaceuticals is continuing to ...

Teva Pharmaceutical (TEVA) stock surges as the company posts better than expected Q3 2025 results and raises the midpoint of ...

Israel-based Phoenix Financial acquired more than 3.5 million additional shares of Teva Pharmaceuticals for an estimated $62.1 million in the third quarter. Post-transaction, the fund reported holding ...

Teva Pharmaceuticals has a new game plan for raising awareness of tardive dyskinesia (TD). | Teva Pharmaceuticals has a new ...

Teva Q3 revenue rose to $4.48 billion, beating estimates, as Austedo and Ajovy boosted growth; 2025 EPS outlook now ...

The Israeli pharmaceutical company, managed by CEO Richard Francis, will publish its third quarter financial results on ...

Evaluate the expected performance of Teva Pharmaceutical Industries (TEVA) for the quarter ended September 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining ...